DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Gou Young | ko |
dc.contributor.author | Augustin, Hellmut G. | ko |
dc.contributor.author | Campochiaro, Peter A. | ko |
dc.date.accessioned | 2022-05-30T06:00:52Z | - |
dc.date.available | 2022-05-30T06:00:52Z | - |
dc.date.created | 2022-05-30 | - |
dc.date.created | 2022-05-30 | - |
dc.date.issued | 2022-05 | - |
dc.identifier.citation | TRENDS IN MOLECULAR MEDICINE, v.28, no.5, pp.347 - 349 | - |
dc.identifier.issn | 1471-4914 | - |
dc.identifier.uri | http://hdl.handle.net/10203/296709 | - |
dc.description.abstract | Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice. | - |
dc.language | English | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.title | Viewpoints: Dual- blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye | - |
dc.type | Article | - |
dc.identifier.wosid | 000796606700002 | - |
dc.identifier.scopusid | 2-s2.0-85127502196 | - |
dc.type.rims | ART | - |
dc.citation.volume | 28 | - |
dc.citation.issue | 5 | - |
dc.citation.beginningpage | 347 | - |
dc.citation.endingpage | 349 | - |
dc.citation.publicationname | TRENDS IN MOLECULAR MEDICINE | - |
dc.identifier.doi | 10.1016/j.molmed.2022.03.004 | - |
dc.contributor.localauthor | Koh, Gou Young | - |
dc.contributor.nonIdAuthor | Augustin, Hellmut G. | - |
dc.contributor.nonIdAuthor | Campochiaro, Peter A. | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Editorial Material | - |
dc.subject.keywordPlus | TIE2 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.